

## Perioperative Management of Aneurysmal Subarachnoid Hemorrhage: A Narrative Review: Erratum

In the article beginning on page 1283 in the December 2020 issue, the statement on page 1286 that “No specific reversal agent is currently available for the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban” is incorrect. The corrected sentence should read: “Andexanet alfa is the specific reversal agent for the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban.”

The authors regret this error. The online version and PDF of the article have been corrected.

DOI: 10.1097/ALN.0000000000003721

### Reference

Sharma D: Perioperative management of aneurysmal subarachnoid hemorrhage: A narrative review. *ANESTHESIOLOGY* 2020; 133:1283–1305

## Complications as a Mediator of the Perioperative Frailty–Mortality Association: Mediation Analysis of a Retrospective Cohort: Erratum

In the Online First article by McIsaac *et al.*, modifications were made to reflect issues of precision missed during the proof process. Frailty scores were adjusted to avoid any false precision, and language was adjusted to properly reflect between-group comparisons (*increase* was changed to *greater*).

The online version and PDF of the article have been corrected.

DOI: 10.1097/ALN.0000000000003737

### Reference

McIsaac DI, Aucoin SD, Bryson GL, Hamilton GM, Lalu MM: Complications as a mediator of the perioperative frailty–mortality association: Mediation analysis of a retrospective cohort. *ANESTHESIOLOGY* 2021 Feb 2 [Epub ahead of print]